The Effects of Xuezhikang and Atorvastatin on Lipid in Patients With Dyslipidemia and Prediabetes

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 398 participants.

Also called NCT06750783

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 398 participants (planned count) (from the registry)
Sponsor
Beijing Tsinghua Chang Gung Hospital (from the registry)
Registry
  • NCT NCT06750783
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06750783. Randomized; no masking; primary purpose treatment. Start 2024-12-31 (actual); primary completion 2026-03-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Effects of Xuezhikang and Atorvastatin on Lipid in Patients With Dyslipidemia and Prediabetes
Acronym
Xuezhikang
Condition
Prediabetic State (IGT)
Intervention (Drug)
Xuezhikang
Intervention (Drug)
Atorvastatin
Lead sponsor
Beijing Tsinghua Chang Gung Hospital (class: other)

Record details

Record id
cardio:ct-nct06750783
Content hash
f233d17d125da9f75416e0faa71e539ec8399c8d84aa2d51002b7946536b3004